Figure 5From: Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometryPlatelet inhibition by ASA, clopidogrel and clopidogrel plus ASA ex vivo. Platelet aggregation as determined by MEA before drug intake (baseline 1; black bars), after oral intake of ASA (100 mg/d for 7 days; white vertically striped grey bars), ASA (100 mg/d for 7 days) plus clopidogrel (600 mg for 4 h; white bars), after 4 weeks of washout (baseline 2; white horizontally striped dark grey bars), and clopidogrel (600 mg for 4 h; grey bars). Blood from five healthy volunteers was exposed to saline (spontaneous aggregation), ADP (6.5 μM), cangrelor (100 nM) + ADP (6.5 μM), AA (0.6 mM), cangrelor (100 nM) + AA (0.6 mM), ASA in vitro (5.4 mM) + AA (0.6 mM). Data are means ± SD (n = 5). The effects of various treatments (after oral intake of ASA, clopidogrel, or both) on platelet aggregation challenged with each stimulus was first tested with overall analysis of variance (n.s. non-significant; §§: p < 0.01; §§§: p < 0.001; on top of the bars) followed by pair comparisons of the individual treatments by the Holm-Sidak-Test, as indicated in brackets under the x-axis (* p < 0.05; ** p < 0.01).Back to article page